S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIBiomarker/Laboratory analysis, TreatmentActive18 and overNCI, OtherCDR0000700624
S1001, U10CA032102, SWOG-S1001, NCT01359592

Trial Description

Summary

RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Comparing results of diagnostic procedures, such as PET scan and CT scan, done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.

PURPOSE: This phase II trial studies how well PET-directed chemotherapy works in treating patients with limited-stage diffuse large B-cell lymphoma.

Further Study Information

OBJECTIVES:

Primary

  • To assess the 5-year progression-free survival (PFS) rate in patients with newly diagnosed limited-stage diffuse, large B-cell lymphoma (DLBCL) using positron emission tomography (PET)/CT scan to direct therapy after 3 courses of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP).

Secondary

  • To evaluate PFS within the PET-positive (+) and PET-negative (-) subgroups of patients with newly diagnosed limited-stage DLBCL.
  • To evaluate toxicity of the protocol treatments in this patient population.
  • To evaluate the response probability in this patient population.
  • To evaluate overall survival in the overall population, and within the PET+ and PET- subgroups.
  • To estimate the rate of upstaging at baseline by PET/CT at baseline among patients newly diagnosed with limited-stage DLBCL by CT imaging and to describe outcomes in patients upstaged by PET/CT at baseline to advanced DLBCL.
  • To describe outcomes in the subgroup of patients upstaged by PET/CT.
  • To evaluate the association of germinal center B-cell subtype (GCB) vs stromal-1 vs stromal-2 gene expression signatures with PFS or overall survival.

OUTLINE: This is a multicenter study. Patients are stratified according to whether the patient was upstaged to advanced stage DLBCL, based on local review of the baseline PET/CT (yes vs no).

Chemotherapy: Patients receive R-CHOP comprising rituximab IV, cyclophosphamide IV over 30-60 minutes, vincristine sulfate IV, and doxorubicin hydrochloride IV on day 1, and prednisone orally on days 1-5. Treatment repeats every 21 days for 3* courses. NOTE: *Patients found to have advanced stage DLBCL based on local review of the baseline PET scan receive 6 courses of R-CHOP.

FDG/PET - Radiotherapy: Patients undergo fludeoxyglucose F 18 positron emission tomography (FDG-PET)/CT scan at baseline, on days 15-18 of course 3, and at 12 weeks after completion of course 3. Patients with complete response (PET scan negative) receive one additional course of R-CHOP as above. Patients with partial response (PET scan positive) undergo involved-field radiotherapy (IFRT) 5 days a week for approximately 4-5 weeks.

Monoclonal antibody: Beginning 3-6 weeks after completion of IFRT, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes and rituximab IV on day 1 and on day 7, 8, or 9.

Patients may undergo blood sample collection at baseline for correlative studies. Bone marrow tissue samples may be also collected for correlative studies.

After completion of study therapy, patients are followed up every 6 months for 2 years and then yearly for 5 years.

Eligibility Criteria

DISEASE CHARACTERISTICS:

  • Patients must have biopsy-proven diffuse large B-cell lymphoma (DLBCL)
  • Adequate sections or a paraffin block from the original diagnostic specimen must be submitted for review by the lymphoma pathology group
  • Lymphoma must express CD20 antigen by either flow cytometry using anti-CD20 antibodies or by immunoperoxidase staining of paraffin sections
  • Patients with primary mediastinal lymphoma or testicular lymphoma are not eligible
  • Patients must have non-bulky stage I or II disease by Ann Arbor classification
  • This staging excludes FDG-PET evaluation
  • Patients who have stage I or II non-bulky disease on diagnostic CT scan, but are upstaged to stage III or IV based on FDG-PET evaluation, are also eligible
  • Patients must have a diagnostic quality contrast-enhanced CT scan of the chest, abdomen, and pelvis AND baseline FDG-PET scan performed within 28 days prior to registration
  • Low-resolution "localization" CT scans performed as part of a combined PET/CT scan are not adequate for enrollment or response determination on this protocol
  • If a patient has an allergy to CT contrast, then a non-enhanced CT will be acceptable
  • Patients must not have clinical evidence of central nervous system (CNS) involvement by lymphoma
  • Any laboratory or radiographic tests performed to assess CNS involvement must be negative and must be performed within 42 days prior to registration
  • Patients may have either measurable or evaluable limited-stage DLBCL
  • Patients rendered free of measurable or evaluable disease by virtue of biopsy (resection) are also eligible
  • If patient has measurable disease it must be documented on the Lymphoma Baseline Tumor Assessment Form (Form #15187)
  • All measurable disease must be assessed within 28 days prior to registration
  • Patients with non-measurable disease in addition to measurable disease must have all non-measurable disease assessed within 42 days prior to registration
  • Patients must have a unilateral or bilateral bone marrow biopsy performed within 42 days prior to registration

PATIENT CHARACTERISTICS:

  • Zubrod performance status 0-2
  • Absolute neutrophil count (ANC) ≥ 1,000/mm³
  • Platelet count ≥ 100,000/mm³
  • Total bilirubin ≤ 2 times upper limit of normal (ULN) (unless due to Gilbert syndrome)
  • Patients must not be pregnant or nursing
  • Women/men of reproductive potential must have agreed to use an effective contraceptive method during the study period
  • Patients must not be known to be HIV-positive
  • No other prior malignancy is allowed except for the following:
  • Adequately treated basal cell or squamous cell skin cancer
  • In situ cervical cancer
  • Adequately treated stage I or II cancer from which the patient is currently in complete remission
  • Any other cancer from which the patient has been disease-free for 5 years

PRIOR CONCURRENT THERAPY:

  • Patients must not have received prior chemotherapy, radiotherapy, or antibody therapy for lymphoma

Trial Contact Information

Trial Lead Organizations/Sponsors

Southwest Oncology Group

  • National Cancer Institute
Daniel O. Persky, Principal Investigator
Megan Hardin
Ph: 2106148808 Ext.1014
Email: mhardin@swog.org

Trial Sites

U.S.A.

Alaska
Fairbanks

Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital

Prakash Vishnu
Ph: 206-342-6954
Email: vmmc.cancer_clinical_research@VirginiaMason.org

Arizona
Tucson

Arizona Cancer Center at University Medical Center North

Thomas P. Miller
Ph: 520-626-9008

Arizona Cancer Center at University of Arizona Health Sciences Center

Thomas P. Miller
Ph: 520-626-9008

California
Duarte

City of Hope Comprehensive Cancer Center

Robert W Chen
Ph: 800-826-4673
Email: becomingapatient@coh.org

Connecticut
Hartford

Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center

Philip J. Stella
Ph: 734-712-4673

New Haven

Yale Cancer Center

Iris Isufi
Ph: 203-785-5702

Georgia
Atlanta

CCOP - Atlanta Regional

Thomas E. Seay
Ph: 404-303-3355

Northside Hospital Cancer Center

Thomas E. Seay
Ph: 404-303-3355

Piedmont Hospital

Thomas E. Seay
Ph: 404-303-3355

Saint Joseph's Hospital of Atlanta

Thomas E. Seay
Ph: 404-303-3355

Austell

WellStar Cobb Hospital

Thomas E. Seay
Ph: 404-303-3355

Columbus

John B. Amos Cancer Center

Thomas E. Seay
Ph: 404-303-3355

Decatur

Charles B. Eberhart Cancer Center at DeKalb Medical Center

Thomas E. Seay
Ph: 404-303-3355

Fayetteville

Piedmont Fayette Hospital

Thomas E. Seay
Ph: 404-303-3355

Lawrenceville

Gwinnett Medical Center

Thomas E. Seay
Ph: 404-303-3355

Marietta

Kennestone Cancer Center at Wellstar Kennestone Hospital

Thomas E. Seay
Ph: 404-303-3355

Riverdale

Southern Regional Medical Center

Thomas E. Seay
Ph: 404-303-3355

Rome

Harbin Clinic Cancer Center - Medical Oncology

Thomas E. Seay
Ph: 404-303-3355

Hawaii
Aiea

Kapiolani Medical Center at Pali Momi

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Ph: 808-586-2979

Ewa Beach

Leeward Radiation Oncology

Jeffrey L. Berenberg
Ph: 808-586-2979

Honolulu

Cancer Research Center of Hawaii

Jeffrey L. Berenberg
Ph: 808-586-2979

Hawaii Medical Center - East

Jeffrey L. Berenberg
Ph: 808-586-2979

Kapiolani Medical Center for Women and Children

Jeffrey L. Berenberg
Ph: 808-586-2979

Kuakini Medical Center

Jeffrey L. Berenberg
Ph: 808-586-2979

OnCare Hawaii, Incorporated - Kuakini

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Ph: 808-586-2979

OnCare Hawaii, Incorporated - Lusitana

Jeffrey L. Berenberg
Ph: 808-586-2979

Queen's Cancer Institute at Queen's Medical Center

Jeffrey L. Berenberg
Ph: 808-586-2979

Straub Clinic and Hospital, Incorporated

Jeffrey L. Berenberg
Ph: 808-586-2979

Lihue

Kauai Medical Clinic

Jeffrey L. Berenberg
Ph: 808-586-2979

Idaho
Boise

Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center

Philip J. Stella
Ph: 734-712-4673

Coeur D'Alene

Kootenai Medical Center

Benjamin Thomas Marchello
Ph: 800-648-6274

Fruitland

Saint Luke's Mountain States Tumor Institute - Fruitland

Paul G. Montgomery
Ph: 800-845-4624

Meridian

Mountain States Tumor Institute - Meridian

Paul G. Montgomery
Ph: 800-845-4624

Nampa

Saint Luke's Mountain States Tumor Institute

Paul G. Montgomery
Ph: 800-845-4624

Post Falls

Kootenai Cancer Center - Post Falls

Benjamin Thomas Marchello
Ph: 800-648-6274

Sandpoint

Kootenai Cancer

Benjamin Thomas Marchello
Ph: 800-648-6274

Twin Falls

Mountain States Tumor Institute at St. Luke's

Paul G. Montgomery
Ph: 800-845-4624

Illinois
Bloomington

Illinois CancerCare - Bloomington

Nguyet A Le-Lindqwister
Ph: 800-793-2262

St. Joseph Medical Center

Nguyet A Le-Lindqwister
Ph: 800-793-2262

Canton

Illinois CancerCare - Canton

Nguyet A Le-Lindqwister
Ph: 800-793-2262

Carbondale

Memorial Hospital of Carbondale

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Carthage

Illinois CancerCare - Carthage

Nguyet A Le-Lindqwister
Ph: 800-793-2262

Centralia

Centralia Oncology Clinic

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Chicago

Louis A. Weiss Memorial Hospital

Keith L. Shulman
Ph: 773-564-5044

Robert H. Lurie Comprehensive Cancer Center at Northwestern University

Adam M Petrich
Ph: 312-695-1301
Email: cancer@northwestern.edu

Decatur

Cancer Care Center of Decatur

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Decatur Memorial Hospital Cancer Care Institute

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Effingham

Crossroads Cancer Center

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Eureka

Illinois CancerCare - Eureka

Nguyet A Le-Lindqwister
Ph: 800-793-2262

Evanston

CCOP - Evanston

David L. Grinblatt
Ph: 847-570-2109

Galesburg

Galesburg Clinic, PC

Nguyet A Le-Lindqwister
Ph: 800-793-2262

InterCommunity Cancer Center of Western Illinois

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Medical and Surgical Specialists, LLC

Nguyet A Le-Lindqwister
Ph: 800-793-2262

Glenview

Glenbrook Hospital

David L. Grinblatt
Ph: 847-570-2109

Highland Park

Hematology Oncology Associates of Illinois-Highland Park

Adam M Petrich
Ph: 312-695-1301
Email: cancer@northwestern.edu

Highland Park Hospital

David L. Grinblatt
Ph: 847-570-2109

Kankakee

Provena St. Mary's Regional Cancer Center - Kankakee

Adam M Petrich
Ph: 312-695-1301
Email: cancer@northwestern.edu

Kewanee

Illinois CancerCare - Kewanee Clinic

Nguyet A Le-Lindqwister
Ph: 800-793-2262

Libertyville

North Shore Oncology and Hematology Associates, Limited - Libertyville

Adam M Petrich
Ph: 312-695-1301
Email: cancer@northwestern.edu

Macomb

Illinois CancerCare - Macomb

Nguyet A Le-Lindqwister
Ph: 800-793-2262

Maywood

Cardinal Bernardin Cancer Center at Loyola University Medical Center

Scott E. Smith
Ph: 708-226-4357

Niles

Cancer Care and Hematology Specialists of Chicagoland - Niles

Adam M Petrich
Ph: 312-695-1301
Email: cancer@northwestern.edu

Ottawa

Illinois CancerCare - Ottawa

Nguyet A Le-Lindqwister
Ph: 800-793-2262

Radiation Oncology of Northern Illinois

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Pekin

Cancer Treatment Center at Pekin Hospital

Nguyet A Le-Lindqwister
Ph: 800-793-2262

Illinois CancerCare - Pekin

Nguyet A Le-Lindqwister
Ph: 800-793-2262

Peoria

Illinois CancerCare - Peoria

Nguyet A Le-Lindqwister
Ph: 800-793-2262

Methodist Medical Center of Illinois

Nguyet A Le-Lindqwister
Ph: 800-793-2262

OSF St. Francis Medical Center

Nguyet A Le-Lindqwister
Ph: 800-793-2262

Peru

Illinois CancerCare - Princeton

Nguyet A Le-Lindqwister
Ph: 800-793-2262

Valley Cancer Center

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Princeton

Illinois CancerCare - Princeton

Nguyet A Le-Lindqwister
Ph: 800-793-2262

Skokie

Hematology Oncology Associates - Skokie

Adam M Petrich
Ph: 312-695-1301
Email: cancer@northwestern.edu

Springfield

Central Illinois Hematology Oncology Center

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Regional Cancer Center at Memorial Medical Center

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Simmons Cooper Cancer Institute

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Springfield Clinic - Main Campus

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Swansea

Cancer Care Specialists of Illinois-Swansea

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Iowa
Sioux City

Siouxland Hematology-Oncology Associates, LLP

Donald Bruce Wender
Ph: 712-252-0088

Kansas
Chanute

Cancer Center of Kansas, PA - Chanute

Shaker R. Dakhil
Ph: 316-262-4467

Dodge City

Cancer Center of Kansas, PA - Dodge City

Shaker R. Dakhil
Ph: 316-262-4467

El Dorado

Cancer Center of Kansas, PA - El Dorado

Shaker R. Dakhil
Ph: 316-262-4467

Fort Scott

Cancer Center of Kansas - Fort Scott

Shaker R. Dakhil
Ph: 316-262-4467

Independence

Cancer Center of Kansas-Independence

Shaker R. Dakhil
Ph: 316-262-4467

Kingman

Cancer Center of Kansas, PA - Kingman

Shaker R. Dakhil
Ph: 316-262-4467

Lawrence

Lawrence Memorial Hospital

Shaker R. Dakhil
Ph: 316-262-4467

Liberal

Cancer Center of Kansas, PA - Liberal

Shaker R. Dakhil
Ph: 316-262-4467

Newton

Cancer Center of Kansas, PA - Newton

Shaker R. Dakhil
Ph: 316-262-4467

Overland Park

Menorah Medical Center

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Saint Luke's Hospital - South

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Parsons

Cancer Center of Kansas, PA - Parsons

Shaker R. Dakhil
Ph: 316-262-4467

Pratt

Cancer Center of Kansas, PA - Pratt

Shaker R. Dakhil
Ph: 316-262-4467

Salina

Cancer Center of Kansas, PA - Salina

Shaker R. Dakhil
Ph: 316-262-4467

Wellington

Cancer Center of Kansas, PA - Wellington

Shaker R. Dakhil
Ph: 316-262-4467

Wichita

Associates in Women's Health, PA - North Hillside

Shaker R. Dakhil
Ph: 316-262-4467

Cancer Center of Kansas, PA - Medical Arts Tower

Shaker R. Dakhil
Ph: 316-262-4467

Cancer Center of Kansas, PA - Wichita

Shaker R. Dakhil
Ph: 316-262-4467

Via Christi Cancer Center at Via Christi Regional Medical Center

Shaker R. Dakhil
Ph: 316-262-4467

Winfield

Cancer Center of Kansas, PA - Winfield

Shaker R. Dakhil
Ph: 316-262-4467

Kentucky
Lexington

University of Kentucky Chandler Medical Center

Gregory P Monohan
Ph: 859-257-3379

Maryland
Baltimore

Alvin and Lois Lapidus Cancer Institute at Sinai Hospital

Roberto F Martinez
Ph: 410-601-6120
Email: pridgely@lifebridgehealth.org

Michigan
Ann Arbor

Saint Joseph Mercy Cancer Center

Philip J. Stella
Ph: 734-712-4673

Dearborn

Oakwood Cancer Center at Oakwood Hospital and Medical Center

Philip J. Stella
Ph: 734-712-4673

Detroit

Van Elslander Cancer Center at St. John Hospital and Medical Center

Philip J. Stella
Ph: 734-712-4673

Flint

Genesys Hurley Cancer Institute

Philip J. Stella
Ph: 734-712-4673

Hurley Medical Center

Philip J. Stella
Ph: 734-712-4673

Jackson

Gayle M. Jacob Cancer Center at Allegiance Health

Philip J. Stella
Ph: 734-712-4673

Lansing

Sparrow Regional Cancer Center

Philip J. Stella
Ph: 734-712-4673

Livonia

St. Mary Mercy Hospital

Philip J. Stella
Ph: 734-712-4673

Pontiac

St. Joseph Mercy Oakland

Philip J. Stella
Ph: 734-712-4673

Port Huron

Mercy Regional Cancer Center at Mercy Hospital

Philip J. Stella
Ph: 734-712-4673

Saginaw

Seton Cancer Institute at Saint Mary's - Saginaw

Philip J. Stella
Ph: 734-712-4673

Warren

St. John Macomb Hospital

Philip J. Stella
Ph: 734-712-4673

Minnesota
Burnsville

Fairview Ridges Hospital

Patrick J. Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Coon Rapids

Mercy and Unity Cancer Center at Mercy Hospital

Patrick J. Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Duluth

CCOP - Duluth

Bret E Friday
Ph: 888-203-7267

Essentia Health - Duluth Clinic

Daniel Nikcevich
Ph: 888-203-7267

Miller - Dwan Medical Center

Daniel Nikcevich
Ph: 888-203-7267

Edina

Fairview Southdale Hospital

Patrick J. Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Fridley

Mercy and Unity Cancer Center at Unity Hospital

Patrick J. Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Hutchinson

Hutchinson Area Health Care

Patrick J. Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Maplewood

HealthEast Cancer Care at St. John's Hospital

Patrick J. Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Minnesota Oncology - Maplewood

Patrick J. Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Minneapolis

Health Partners Inc

Patrick J. Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Hennepin County Medical Center - Minneapolis

Patrick J. Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Virginia Piper Cancer Institute at Abbott - Northwestern Hospital

Patrick J. Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

New Ulm

New Ulm Medical Center

Patrick J. Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Robbinsdale

Humphrey Cancer Center at North Memorial Outpatient Center

Patrick J. Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Saint Louis Park

Park Nicollet Cancer Center

Patrick J. Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Saint Paul

Regions Hospital Cancer Care Center

Patrick J. Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

United Hospital

Patrick J. Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Shakopee

St. Francis Cancer Center at St. Francis Medical Center

Patrick J. Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Stillwater

Lakeview Hospital

Patrick J. Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Waconia

Ridgeview Medical Center

Patrick J. Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Willmar

Willmar Cancer Center at Rice Memorial Hospital

Patrick J. Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Woodbury

Minnesota Oncology - Woodbury

Patrick J. Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Missouri
Bonne Terre

Parkland Health Center-Bonne Terre

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Cape Girardeau

Saint Francis Medical Center

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Southeast Cancer Center

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Independence

Independence Regional Health Center

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Jefferson City

Goldschmidt Cancer Center

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Kansas City

Heartland Hematology Oncology Associates, Incorporated

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Research Medical Center

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Saint Luke's Hospital

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Lee's Summit

Saint Luke's East - Lee's Summit

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Liberty

Parvin Radiation Oncology

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Saint Joseph

Heartland Regional Medical Center

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Saint Louis

Missouri Baptist Cancer Center

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis

Nancy L. Bartlett
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Sainte Genevieve

Sainte Genevieve County Memorial Hospital

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Sullivan

Missouri Baptist Sullivan Hospital

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Sunset Hills

Missouri Baptist Outpatient Center-Sunset Hills

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Montana
Billings

Billings Clinic Cancer Center - 801 N 29th Street

Benjamin Thomas Marchello
Ph: 800-648-6274

CCOP - Montana Cancer Consortium

Benjamin Thomas Marchello
Ph: 800-648-6274

St. Vincent Healthcare Cancer Care Services

Benjamin Thomas Marchello
Ph: 800-648-6274

Bozeman

Bozeman Deaconess Cancer Center

Benjamin Thomas Marchello
Ph: 800-648-6274

Butte

St. James Healthcare Cancer Care

Benjamin Thomas Marchello
Ph: 800-648-6274

Great Falls

Benefis Sletten Cancer Institute

Benjamin Thomas Marchello
Ph: 800-648-6274

Helena

St. Peter's Hospital

Benjamin Thomas Marchello
Ph: 800-648-6274

Kalispell

Kalispell Regional Medical Center

Benjamin Thomas Marchello
Ph: 800-648-6274

Missoula

Community Medical Center

Benjamin Thomas Marchello
Ph: 800-648-6274

Montana Cancer Center at St. Patrick Hospital and Health Sciences Center

Benjamin Thomas Marchello
Ph: 800-648-6274

New York
Middletown

Tucker Center for Cancer Care at Orange Regional Medical Center

Jeffrey M. Stewart
Ph: 845-342-7609

Rochester

James P. Wilmot Cancer Center at University of Rochester Medical Center

Jonathan W Friedberg
Ph: 585-275-5830

North Carolina
Chapel Hill

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill

Steven I Park
Ph: 877-668-0683
Email: cancerclinicaltrials@med.unc.edu

Goldsboro

Wayne Memorial Hospital, Incorporated

James N. Atkins
Ph: 919-580-0000

Hendersonville

Park Ridge Hospital Breast Health Center

James Dewitt Bearden
Ph: 800-486-5941

Raleigh

Rex Cancer Center at Rex Hospital

Jeffrey Major Crane
Ph: 919-784-7209

Statesville

Iredell Memorial Hospital

Ruby A. Grimm
Ph: 704-873-5661

North Dakota
Fargo

Roger Maris Cancer Center at MeritCare Hospital

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Ph: 701-234-6161

Sanford Clinic North-Fargo

Preston D. Steen
Ph: 701-234-6161

Ohio
Canton

Mercy Cancer Center at Mercy Medical Center

Mitchell Haut
Ph: 888-293-4673

Pennsylvania
Danville

Geisinger Cancer Institute at Geisinger Health

Edward J Gorak
Ph: 570-271-5251

Hazleton

Geisinger Hazleton Cancer Center

Edward J Gorak
Ph: 570-271-5251

Philadelphia

Fox Chase Cancer Center - Philadelphia

Stefan K Barta
Ph: 215-728-4790

Temple Cancer Center at Temple University Hospital

Stefan K Barta
Ph: 215-728-4790

South Carolina
Greenville

Bon Secours St. Francis Health System

James Dewitt Bearden
Ph: 800-486-5941

Cancer Centers of the Carolinas - Faris Road

Jeffrey Kent Giguere
Ph: 864-241-6251

Cancer Centers of the Carolinas - Grove Commons

Jeffrey Kent Giguere
Ph: 864-241-6251

CCOP - Greenville

Jeffrey Kent Giguere
Ph: 864-241-6251

Greenville Memorial Hospital

Jeffrey Kent Giguere
Ph: 864-241-6251

Saint Francis Cancer Center

James Dewitt Bearden
Ph: 800-486-5941

Greer

Cancer Centers of the Carolinas - Greer Radiation Oncology

Jeffrey Kent Giguere
Ph: 864-241-6251

Seneca

Cancer Centers of the Carolinas - Seneca

Jeffrey Kent Giguere
Ph: 864-241-6251

Spartanburg

Cancer Centers of the Carolinas - Spartanburg

Jeffrey Kent Giguere
Ph: 864-241-6251

Gibbs Regional Cancer Center at Spartanburg Regional Medical Center

James Dewitt Bearden
Ph: 800-486-5941

South Dakota
Sioux Falls

Sanford Cancer Center at Sanford USD Medical Center

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Ph: 701-234-6161

Washington
Kirkland

Cascade Cancer Center at Evergreen Hospital Medical Center

Oliver W Press
Ph: 800-422-6237

Seattle

CCOP - Virginia Mason Research Center

Prakash Vishnu
Ph: 206-342-6954
Email: vmmc.cancer_clinical_research@VirginiaMason.org

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Oliver W Press
Ph: 800-422-6237

Pacific Medical Center

Prakash Vishnu
Ph: 206-342-6954
Email: vmmc.cancer_clinical_research@VirginiaMason.org

Seattle Cancer Care Alliance

Oliver W Press
Ph: 800-422-6237

University Cancer Center at University of Washington Medical Center

Oliver W Press
Ph: 800-422-6237

Virginia Mason Medical Center

Prakash Vishnu
Ph: 206-342-6954
Email: vmmc.cancer_clinical_research@VirginiaMason.org

West Virginia
Morgantown

Mary Babb Randolph Cancer Center at West Virginia University Hospitals

Mehdi Hamadani
Ph: 414-805-4380
Email: sfilburn@hsc.wvu.edu

Wisconsin
La Crosse

Gundersen Lutheran Center for Cancer and Blood

Kurt Oettel
Ph: 608-775-2385
Email: cancerctr@gundluth.org

New Richmond

Cancer Center of Western Wisconsin

Joseph W Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Wyoming
Cody

Big Horn Basin Cancer Center

Benjamin Thomas Marchello
Ph: 800-648-6274

Billings Clinic-Cody

Benjamin Thomas Marchello
Ph: 800-648-6274

Sheridan

Welch Cancer Center at Sheridan Memorial Hospital

Benjamin Thomas Marchello
Ph: 800-648-6274

Link to the current ClinicalTrials.gov record.
NLM Identifier NCT01359592
ClinicalTrials.gov processed this data on May 11, 2015

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.